The Institute for Clinical and Economic Review’s (ICER) Midwest Comparative Effective Public Advisory Council (CEPAC) will hold is inaugural meeting on May 26, 2016 in St. Louis “to discuss the comparative clinical effectiveness and value of therapies of multiple myeloma.”  The goal is to create recommendations that health insurers (or payers) will use to determine reimbursement levels for drugs used in myeloma treatment.  Since the public announcement of ICER’s plan in February 2016, the draft reports have been strongly criticized by myeloma specialists, pharmaceutical companies, and more recently, patient advocates.  Steven Pearson will discuss ICER’s perspective, addressing critics of ICER’s methodology, process, definitions of value, and, as of now, the lack of inclusion of patient views.